“Our vaccine is ideal for boosting,” Chief Executive Officer
Erck said the Gaithersburg, Maryland-based company has solved manufacturing problems that delayed its vaccine this year and expects to be able to produce 150 million doses a month with partner Serum Institute of India by December.
Novavax was among the companies that received ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.